Louis Basenese helped direct over $1 billion in institutional capital at Morgan Stanley before leaving Wall Street for Silicon Valley. Now, as the world’s premier venture capital analyst, Louis tracks early investment opportunities born from technological breakthroughs and new drug discoveries. His deep expertise of patents, buyouts, takeovers, mergers & acquisitions, Reg-D offerings, and crowdfunding has given Louis genuine star power on frontline media outlets like CNBC. Louis serves as the Investment Director for his wildly popular publications True Alpha, Extreme Alpha, and VentureCap Strategist.
Before the general public can benefit from the most revolutionary gene-editing technique of the 21st century, the U.S. Patent and Trademark Office has to figure out who the technology even belongs to — and who will profit.
Donald Trump ran a campaign on hyperbole and vagueness. Now as he prepares to take office, we take a closer look at his contradictory statements on science to make sense of the future of our favored industries.
It’s easy to dismiss celebrities and politicians as having hidden agendas. On the other hand, scientists that uncover cold, hard facts, deserve our respect for their endeavors. But respect is not worship.